The hidden potential of glycomarkers: Glycosylation studies in the service of cancer diagnosis and treatment

Changes in the glycosylation process appear early in carcinogenesis and evolve with the growth and spread of cancer. The correlation of the characteristic glycosylation signature with the tumor stage and the appropriate therapy choice is important in translational medicine. Oncologists also pay attention to extracellular vesicles as reservoirs of new cancer glycomarkers that can be potent for cancer diagnosis/prognosis. In this review, Karolina Grzesik, Marcelina Janik, Dorota Hoja-Łukowicz from Jagiellonian University collect glycomarkers used in oncology and show their new glycoforms of improved clinical relevance, summarize current knowledge on the biological functions of glycoepitopes in cancer-derived extracellular vesicles and their potential use in clinical practice. Is glycomics a future of cancer diagnosis? It may be but in combination with other omics analyses than alone.

See the full review here: The hidden potential of glycomarkers: Glycosylation studies in the service of cancer diagnosis and treatment

Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals

Fascinating discovery from BASF on increasing space-time-yield, carbon-conversion-efficiency, and carbon substrate flexibility in the production of fine chemicals. They found a positive effect of increased cAMP levels and/or manipulating the PTS system on the above characteristics achieved by de-regulating adenylate cyclase cyaa by deleting the C-terminal regulatory region leading to increased cAMP levels or deleting the Crr protein activity (carbohydrate repression resistance) which regulates the carbohydrate utilization system. Both lead to increased 2-fucosyllactoe and 6-sialyllactose production (human milk oligosaccharides) and increase carbohydrate usage.
Hartwig SchroederPeter Ödman]; Georg WandreyChristian DietzschDominik SatoryMatthew BlankschienJens Plassmeier et al.

See the full patent on Espacenet

Fucosyltransferase-specific inhibition using fucose mimetics

Fascinating joint invention by Università degli Studi di Firenze and Florida International University – Robert Sackstein MD,PhDBarbara Richichi, and Kyle Martin.
The specific glycomimetic fucosyltransferase inhibitors created are proposed for treatment of a variety of diseases, like acute inflammatory disease, chronic inflammatory disease, diabetes, cystic fibrosis, or a cancer via a modification of fucosylated cell surface glycoconjugates.

See the full patent here

Sugar-decorated carbon dots: a novel tool for targeting immunomodulatory receptor

Griffith University (Oren CooperDechao ChenThomas HaselhorstJoseph Tiralongo et al) and University of Bremen released common findings on creating multivalent siglec probes through the decoration of α(2,6)-sialyllactose ligands on inherently fluorescent carbon dots capable of generating a significant cytotoxic effect on Burkitt’s Lymphoma (BL) Daudi B cells.

See the full article here

Prostate-specific membrane antigen (PSMA) ligands comprising an amylase cleavable linker

Using sugars in a prodrug concept is a fascinating idea as these compounds can bring so much to the table like improve stability, PK, or help in targeting. In this patent from Heidelberg University oligosaccharide conjugated prostate-specific membrane antigens are described where the bonds are cleaved by amylase in the body.

See the patent on espacenet